Previous Article | Next Article ![]()
Infection and Immunity, May 1999, p. 2131-2137, Vol. 67, No. 5
Noguchi Memorial Institute for Medical
Research, University of Ghana, Legon, Ghana1;
Centre for Medical Parasitology, Department of Infectious
Diseases, Copenhagen University Hospital (Rigshospitalet), and
Institute of Medical Microbiology and Immunology, University of
Copenhagen, Copenhagen, Denmark2; and
Department of Infectious and Tropical Diseases, London School
of Hygiene and Tropical Medicine, London, United
Kingdom3
Received 11 December 1998/Returned for modification 21 January
1999/Accepted 12 February 1999
The 19-kDa conserved C-terminal part of the Plasmodium
falciparum merozoite surface protein 1 (PfMSP119) is
a malaria vaccine candidate antigen, and human antibody responses to
PfMSP119 have been associated with protection against
clinical malaria. In this longitudinal study carried out in an area of
stable but seasonal malaria transmission with an estimated
parasite inoculation of about 20 infective bites/year, we monitored 266 3- to 15-year-old Ghanaian children clinically and parasitologically
over a period of 18 months. Blood samples were collected at the
beginning of the study before the major malaria season in April and
after the season in November. Using enzyme-linked immunosorbent assay,
we measured antibody responses to recombinant gluthathione
S-transferase-PfMSP119 fusion proteins
corresponding to the Wellcome and MAD20 allelic variants in these
samples. Prevalence of antibodies recognizing the Wellcome 19 construct
containing both epidermal growth factor (EGF)-like motifs in
Wellcome type PfMSP119 was about 30%. Prevalence of
antibodies to constructs containing only the first EGF domain from
either Wellcome or MAD20 type PfMSP119 was about 15%,
whereas antibodies recognizing a construct containing only the second EGF domain of MAD20 type PfMSP119 was found in only about
4% of the donors. Neither the prevalence nor the levels of any of
the antibody specificities varied significantly with season,
age, or sex. Significantly, and in contrast to previous reports
from other parts of West Africa, we found no evidence of an
association between antibody responses to PfMSP119
and clinical protection against malaria.
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Levels of Antibody to Conserved Parts of Plasmodium
falciparum Merozoite Surface Protein 1 in Ghanaian Children Are
Not Associated with Protection from Clinical Malaria
*
Corresponding author. Mailing address: Department of
Infectious Diseases M7641, Rigshospitalet, Tagensvej 20, 2200 Copenhagen N, Denmark. Phone: 45 35 45 73 75. Fax: 45 35 45 76 44. E-mail: ddcmp{at}rh.dk.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|